Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Apolipoprotein A-I(Milano): current perspectives.

Giulia Chiesa1, Cesare R Sirtori

  • 1Department of Pharmacological Sciences, University of Milano, via Balzaretti 9, 20133, Milano, Italy. giulia.chiesa@unimi.it

Current Opinion in Lipidology
|March 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Organobodies: a robust and size-controllable system for generating scalable hiPSC-derived liver organoids for drug toxicity screening.

Biofabrication·2026
Same author

Integrated high-throughput miRNomics and lipidomics in mice with altered lipoprotein metabolism.

Atherosclerosis·2026
Same author

Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction.

Cardiovascular diabetology·2025
Same author

The role of the PPAR system in diabetic cardiovascular risk and beyond.

Current opinion in endocrinology, diabetes, and obesity·2025
Same author

Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE<sup>-/-</sup> mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

The lack of apoA-I in apoE-KO mice affects the liver transcriptome.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2025

Recombinant apolipoprotein A-I(Milano) effectively reduces arterial plaque and increases HDL cholesterol. This synthetic HDL therapy shows promise for treating atherosclerosis and vascular diseases.

Area of Science:

  • Cardiovascular Research
  • Biotechnology
  • Atherosclerosis Prevention

Background:

  • High-density lipoprotein (HDL) strategies are key in atherosclerosis prevention.
  • The mutant apolipoprotein A-I(Milano) is linked to lower coronary disease rates.
  • Recombinant apolipoprotein A-I(Milano) shows significant atheroprotective effects in models.

Purpose of the Study:

  • To review experimental studies on recombinant apolipoprotein A-I(Milano) for vascular disease treatment.
  • To update on the therapeutic potential of apolipoprotein A-I(Milano) in atherosclerosis.

Main Methods:

  • Review of experimental studies involving recombinant apolipoprotein A-I(Milano).
  • Analysis of data from animal models (apolipoprotein E-deficient mice, rabbits).

Related Experiment Videos

  • Examination of clinical findings on HDL free cholesterol increase post-infusion.

    • Main Results:

    • Single-dose liposome-formulated recombinant apolipoprotein A-I(Milano) reduced atheromas by up to 30% in animal models.
    • A 90-minute infusion in rabbits significantly reduced carotid focal lesions.
    • Observed increase in HDL free cholesterol and prolonged presence of the recombinant product in lesions (>72h).

    Conclusions:

    • Recombinant apolipoprotein A-I(Milano), as synthetic HDL, directly removes arterial cholesterol.
    • Demonstrated efficacy in experimental animals and clinical findings of increased HDL free cholesterol.
    • Well-tolerated and non-immunogenic, with ongoing Phase II trials for 'HDL therapy' proof of principle.